Re: WHO Classification of Tumours, 5th Edition, Volume 8: Urinary and Male Genital Tumours
- 10 May 2023
- journal article
- editorial
- Published by Elsevier in European Urology
- Vol. 84 (3) , 348-349
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)Journal of Clinical Oncology, 2023
- WHO 2022 landscape of papillary and chromophobe renal cell carcinomaHistopathology, 2022
- A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trialThe Lancet, 2021
- Efficacy of Savolitinib vs Sunitinib in Patients WithMET-Driven Papillary Renal Cell CarcinomaJAMA Oncology, 2020
- Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell CancerJournal of Clinical Oncology, 2017
- Comprehensive Molecular Characterization of Papillary Renal-Cell CarcinomaNew England Journal of Medicine, 2016